Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Firmagon
Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist used to treat advanced prostate cancer. It works by blocking the GnRH receptors in the pituitary gland, which reduces the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to a rapid decrease in testosterone levels, which helps to slow or stop the growth of prostate cancer cells. Degarelix is administered as a subcutaneous injection.
For the treatment of advanced hormone-dependent prostate cancer.
Outcome:
Increased degarelix levels
Mechanism:
Reduced degarelix metabolism
Outcome:
Increased risk of urinary retention
Mechanism:
Additive anticholinergic effects
Outcome:
May decrease degarelix absorption
Mechanism:
Binding of degarelix in the GI tract
Most likely new formulation: Long-acting injectable degarelix (2025, 70% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood that degarelix will maintain its current regulatory status for the next 5 years.
Hormone Antagonist, GnRH Antagonist
Synthetic decapeptide